Bio-Techne (TECH) to Release Quarterly Earnings on Wednesday

Key Points

• Bio-Techne is expected to report Q4 2026 results before the market opens on Wednesday, August 5. Analysts project earnings of $0.52 per share on revenue of approximately $314.7 million.
• The company’s previous quarter fell short of expectations, with EPS of $0.53 versus the $0.55 consensus and revenue of $311.4 million versus estimates of $316.1 million; revenue declined 1.5% year over year.
• Shares recently opened at $72.07, near their 52-week high, while analysts maintain a consensus “Hold” rating and an average price target of $68.08. Bio-Techne also pays a quarterly dividend of $0.08, yielding about 0.4%.

Bio-Techne (NASDAQ:TECH - Get Free Report) is projected to issue its Q4 2026 results before the market opens on Wednesday, August 5th. Analysts expect Bio-Techne to post earnings of $0.52 per share and revenue of $314.6510 million for the quarter. Investors can check the company's upcoming Q4 2026 earning results page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 9:00 AM ET.

Bio-Techne (NASDAQ:TECH - Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.53 earnings per share for the quarter, missing the consensus estimate of $0.55 by ($0.02). The firm had revenue of $311.42 million for the quarter, compared to analyst estimates of $316.11 million. Bio-Techne had a return on equity of 13.57% and a net margin of 9.05%.Bio-Techne's revenue for the quarter was down 1.5% compared to the same quarter last year. During the same period in the previous year, the business posted $0.56 EPS. On average, analysts expect Bio-Techne to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Bio-Techne Stock Performance

Shares of NASDAQ TECH opened at $72.07 on Wednesday. The business has a fifty day simple moving average of $61.56 and a 200 day simple moving average of $58.89. The company has a current ratio of 4.49, a quick ratio of 3.18 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $11.28 billion, a price-to-earnings ratio of 104.45, a PEG ratio of 8.53 and a beta of 1.29. Bio-Techne has a one year low of $43.19 and a one year high of $72.16.

Bio-Techne Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, May 29th. Shareholders of record on Monday, May 18th were issued a $0.08 dividend. This represents a $0.32 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend was Monday, May 18th. Bio-Techne's payout ratio is 46.38%.

Institutional Investors Weigh In On Bio-Techne

Institutional investors and hedge funds have recently made changes to their positions in the company. Measured Wealth Private Client Group LLC acquired a new stake in shares of Bio-Techne during the 3rd quarter worth about $32,000. iSAM Funds UK Ltd acquired a new position in Bio-Techne in the third quarter valued at about $33,000. EverSource Wealth Advisors LLC boosted its position in Bio-Techne by 506.3% in the second quarter. EverSource Wealth Advisors LLC now owns 673 shares of the biotechnology company's stock valued at $35,000 after buying an additional 562 shares in the last quarter. Los Angeles Capital Management LLC bought a new stake in Bio-Techne during the fourth quarter worth about $39,000. Finally, Itau Unibanco Holding S.A. grew its stake in Bio-Techne by 81.5% during the fourth quarter. Itau Unibanco Holding S.A. now owns 1,009 shares of the biotechnology company's stock worth $59,000 after buying an additional 453 shares during the last quarter. Institutional investors and hedge funds own 98.95% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on TECH shares. Citigroup cut shares of Bio-Techne from a "buy" rating to a "neutral" rating and increased their price objective for the company from $70.00 to $73.00 in a research note on Friday, June 26th. Benchmark lowered shares of Bio-Techne from a "buy" rating to a "hold" rating in a research report on Tuesday, June 30th. Weiss Ratings raised shares of Bio-Techne from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday, May 7th. Stephens set a $73.00 price target on shares of Bio-Techne and gave the stock an "equal weight" rating in a research report on Friday, June 26th. Finally, Piper Sandler started coverage on shares of Bio-Techne in a research note on Thursday, June 11th. They set a "neutral" rating and a $65.00 price target for the company. Three equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $68.08.

About Bio-Techne

Bio-Techne Corporation NASDAQ: TECH is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.